New cancer clinical trial: Converting HR+ Breast Cancer Into an Individualized Vaccine

Published on: January 15, 2019 at 12:00PM
Condition:   Breast Cancer
Interventions:   Radiation: Focal Radiation therapy;   Drug: Pembrolizumab (200mg IV for 30 minutes;   Biological: CDX-301
Sponsor:   Weill Medical College of Cornell University
Not yet recruiting
http://bit.ly/2RyhPtN